<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01513122</url>
  </required_header>
  <id_info>
    <org_study_id>2L body comp sub-study</org_study_id>
    <nct_id>NCT01513122</nct_id>
  </id_info>
  <brief_title>Bone and Body Comp: A Sub Study of the SECOND-LINE Study</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kirby Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kirby Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The use of anti HIV drugs (ART), and in particular a class of drugs known as nucleoside
      reverse transcriptase inhibitors (N(t)RTI), has been associated with changes in body fat and
      in particular loss of peripheral fat in the limbs. Low bone mineral density and osteoporosis
      are also common in HIV-infected patients. There appears to be some association between ART
      and bone loss, but this is poorly understood and requires further research. The SECOND-LINE
      study provides an opportunity to examine if a new anti-HIV drug (raltegravir) can result in
      greater increase in limb fat than a drug regimen containing N(t)RTI, which is currently
      standard of care. This study also provides an opportunity to examine if additional bone loss
      occurs with the second regimen of anti-HIV drugs and whether non-N(t)RTI regimens of ART used
      in second line therapy result in more or less bone loss than use of other classes of anti-HIV
      drugs such as protease inhibitors or N(t)RTI combinations.

      It is hypothesized that subjects randomised into Raltegravir arm will demonstrate greater
      increases in limb fat and smaller reductions in bone density at the proximal femur over 48
      weeks than those randomised into the control arm (LPV/r + 2-3N(t)RTIs).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2010</start_date>
  <completion_date type="Actual">August 2013</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Bone Mineral Density Changes Over 48 Weeks as Measured by DXA Scan</measure>
    <time_frame>May 2013</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Limbs Fat Changes Over 48 Weeks as Measured by DXA Scan</measure>
    <time_frame>May 2013</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Total Body Fat Changes Over 48 Weeks as Measured by DXA Scan</measure>
    <time_frame>May 2013</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Triglycerides Changes Over 48 Weeks as Measured by DXA Scan</measure>
    <time_frame>May 2013</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Total Cholesterol Changes Over 48 Weeks as Measured by DXA Scan</measure>
    <time_frame>May 2013</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Glucose Changes Over 48 Weeks as Measured by DXA Scan</measure>
    <time_frame>May 2013</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">211</enrollment>
  <condition>HIV</condition>
  <arm_group>
    <arm_group_label>Arm 1. Lopinavir / ritonavir + 2-3N(t)RTI</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2. Lopinavir /ritonavir + raltegravir</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lopinavir / ritonavir + 2-3N(t)RTI</intervention_name>
    <description>LPV/r 200mg/50mg 4 tabs once daily or 2 tabs twice daily + 2-3 N(t)RTI</description>
    <arm_group_label>Arm 1. Lopinavir / ritonavir + 2-3N(t)RTI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lopinavir /ritonavir + raltegravir</intervention_name>
    <description>LPV/r 200mg/50mg 4 tabs once daily or 2 tabs twice daily + raltegravir 400mg 1 tablet twice daily.</description>
    <arm_group_label>Arm 2. Lopinavir /ritonavir + raltegravir</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Second-Line main study identifier: NCT00931463

        Inclusion Criteria:

          1. HIV-1 positive by licensed diagnostic test

          2. Aged 16 years or older (or minimum age as determined by local regulations or as legal
             requirements dictate)

          3. Have received first antiretroviral regimen consisting of an NNRTI plus 2N(t)RTIs for ≥
             24 weeks

          4. No change in antiretroviral therapy within 12 weeks prior to screening

          5. Failed first-line NNRTI + 2N(t)RTI combination therapy according to virological
             criteria defined by two consecutive (≥7 days apart) HIV RNA results of &gt; 500 copies/mL

          6. No prior or current exposure to HIV protease inhibitors and/or HIV integrase
             inhibitors

          7. Able to provide written informed consent

        Exclusion Criteria:

          1. The following laboratory variables:

               -  absolute neutrophil count (ANC) &lt; 500 cells/µL

               -  hemoglobin &lt; 7.0 g/dL

               -  platelet count &lt; 50,000 cells/µL

               -  ALT &gt; 5 x ULN

          2. Pregnant or nursing mothers

          3. Participants with active viral hepatitis B infection defined by the presence in serum
             of hepatitis B surface antigen

          4. Use of immunomodulators within 30 days prior to screening

          5. Use of any prohibited medications (rifampicin, midazolam, triazolam, cisapride,
             pimozide, amiodarone, dihydroergotamine, ergotamine, ergonovine, methylergonovine,
             astemizole, terfenadine, vardenafil, and St. John's wort)

          6. Intercurrent illness requiring hospitalisation

          7. Active opportunistic disease not under adequate control in the opinion of the site
             Principal Investigator

          8. Participants with current alcohol or illicit substance abuse that in the opinion of
             the site Principal Investigator might adversely affect participation in the study

          9. Participants deemed by the site Principal Investigator unlikely to be able to remain
             in follow-up for the protocol-defined period
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paddy Mallon</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mater Misericordiae University Hospital, Dublin</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Waldo Belloso</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Italiano, Argentina</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Samuel Ferret</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hopital Saint-Louis, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Praphan Phanuphak</last_name>
    <role>Principal Investigator</role>
    <affiliation>HIV-NAT Program on AIDS - Thai Red Cross, Bangkok</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jennifer Hoy</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Alfred</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CEADI</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>YRGCare Medical Centre</name>
      <address>
        <city>Chennai</city>
        <zip>600113</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Malaya Medical Centre</name>
      <address>
        <city>Kuala Lumpur</city>
        <zip>50603</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JOSHA Research</name>
      <address>
        <city>Bloemfontain</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Desmond Tutu HIV Foundation</name>
      <address>
        <city>Cape Town</city>
        <zip>7925</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chris Hani Baragwanath Hospital</name>
      <address>
        <city>Soweto</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HIV-NAT Program on AIDS - Thai Red Cross</name>
      <address>
        <city>Bangkok</city>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>India</country>
    <country>Malaysia</country>
    <country>South Africa</country>
    <country>Thailand</country>
  </location_countries>
  <results_reference>
    <citation>Martin A, Moore C, Mallon PW, Hoy J, Emery S, Belloso W, Phanuphak P, Ferret S, Cooper DA, Boyd MA; Second Line study team. Bone mineral density in HIV participants randomized to raltegravir and lopinavir/ritonavir compared with standard second line therapy. AIDS. 2013 Sep 24;27(15):2403-11. doi: 10.1097/01.aids.0000432534.47217.b4.</citation>
    <PMID>23921615</PMID>
  </results_reference>
  <results_reference>
    <citation>Martin A, Moore CL, Mallon PW, Hoy JF, Emery S, Belloso WH, Phanuphak P, Ferret S, Cooper DA, Boyd MA; Second-Line Study Team. HIV lipodystrophy in participants randomised to lopinavir/ritonavir (LPV/r) +2-3 nucleoside/nucleotide reverse transcriptase inhibitors (N(t)RTI) or LPV/r + raltegravir as second-line antiretroviral therapy. PLoS One. 2013 Oct 30;8(10):e77138. doi: 10.1371/journal.pone.0077138. eCollection 2013.</citation>
    <PMID>24204757</PMID>
  </results_reference>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 16, 2012</study_first_submitted>
  <study_first_submitted_qc>January 19, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 20, 2012</study_first_posted>
  <results_first_submitted>December 1, 2013</results_first_submitted>
  <results_first_submitted_qc>December 1, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 17, 2014</results_first_posted>
  <last_update_submitted>December 1, 2013</last_update_submitted>
  <last_update_submitted_qc>December 1, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 17, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Lopinavir</mesh_term>
    <mesh_term>Raltegravir Potassium</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Arm 1. Lopinavir / Ritonavir + 2-3N(t)RTI</title>
          <description>Lopinavir / ritonavir + 2-3N(t)RTI: LPV/r 200mg/50mg 4 tabs once daily or 2 tabs twice daily + 2-3 N(t)RTI</description>
        </group>
        <group group_id="P2">
          <title>Arm 2. Lopinavir /Ritonavir + Raltegravir</title>
          <description>Lopinavir /ritonavir + raltegravir: LPV/r 200mg/50mg 4 tabs once daily or 2 tabs twice daily + raltegravir 400mg 1 tablet twice daily.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="102"/>
                <participants group_id="P2" count="108"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="91"/>
                <participants group_id="P2" count="105"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arm 1. Lopinavir / Ritonavir + 2-3N(t)RTI</title>
          <description>Lopinavir / ritonavir + 2-3N(t)RTI: LPV/r 200mg/50mg 4 tabs once daily or 2 tabs twice daily + 2-3 N(t)RTI</description>
        </group>
        <group group_id="B2">
          <title>Arm 2. Lopinavir /Ritonavir + Raltegravir</title>
          <description>Lopinavir /ritonavir + raltegravir: LPV/r 200mg/50mg 4 tabs once daily or 2 tabs twice daily + raltegravir 400mg 1 tablet twice daily.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="102"/>
            <count group_id="B2" value="108"/>
            <count group_id="B3" value="210"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38.5" spread="7.8"/>
                    <measurement group_id="B2" value="38.5" spread="7.7"/>
                    <measurement group_id="B3" value="38.5" spread="7.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="63"/>
                    <measurement group_id="B3" value="110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Bone Mineral Density Changes Over 48 Weeks as Measured by DXA Scan</title>
        <time_frame>May 2013</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1. Lopinavir / Ritonavir + 2-3N(t)RTI</title>
            <description>Lopinavir / ritonavir + 2-3N(t)RTI: LPV/r 200mg/50mg 4 tabs once daily or 2 tabs twice daily + 2-3 N(t)RTI</description>
          </group>
          <group group_id="O2">
            <title>Arm 2. Lopinavir /Ritonavir + Raltegravir</title>
            <description>Lopinavir /ritonavir + raltegravir: LPV/r 200mg/50mg 4 tabs once daily or 2 tabs twice daily + raltegravir 400mg 1 tablet twice daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Bone Mineral Density Changes Over 48 Weeks as Measured by DXA Scan</title>
          <units>percentage of BMD change</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="97"/>
                <count group_id="O2" value="107"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.2" lower_limit="-6.7" upper_limit="-3.8"/>
                    <measurement group_id="O2" value="-2.9" lower_limit="-4.3" upper_limit="-1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Limbs Fat Changes Over 48 Weeks as Measured by DXA Scan</title>
        <time_frame>May 2013</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1. Lopinavir / Ritonavir + 2-3N(t)RTI</title>
            <description>Lopinavir / ritonavir + 2-3N(t)RTI: LPV/r 200mg/50mg 4 tabs once daily or 2 tabs twice daily + 2-3 N(t)RTI</description>
          </group>
          <group group_id="O2">
            <title>Arm 2. Lopinavir /Ritonavir + Raltegravir</title>
            <description>Lopinavir /ritonavir + raltegravir: LPV/r 200mg/50mg 4 tabs once daily or 2 tabs twice daily + raltegravir 400mg 1 tablet twice daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Limbs Fat Changes Over 48 Weeks as Measured by DXA Scan</title>
          <units>percentage of limb fat change</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="94"/>
                <count group_id="O2" value="107"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.7" lower_limit="5.3" upper_limit="25.9"/>
                    <measurement group_id="O2" value="21.1" lower_limit="11.1" upper_limit="31.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Total Body Fat Changes Over 48 Weeks as Measured by DXA Scan</title>
        <time_frame>May 2013</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1. Lopinavir / Ritonavir + 2-3N(t)RTI</title>
            <description>Lopinavir / ritonavir + 2-3N(t)RTI: LPV/r 200mg/50mg 4 tabs once daily or 2 tabs twice daily + 2-3 N(t)RTI</description>
          </group>
          <group group_id="O2">
            <title>Arm 2. Lopinavir /Ritonavir + Raltegravir</title>
            <description>Lopinavir /ritonavir + raltegravir: LPV/r 200mg/50mg 4 tabs once daily or 2 tabs twice daily + raltegravir 400mg 1 tablet twice daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Total Body Fat Changes Over 48 Weeks as Measured by DXA Scan</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="94"/>
                <count group_id="O2" value="107"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" lower_limit="0.2" upper_limit="2.7"/>
                    <measurement group_id="O2" value="2.1" lower_limit="0.9" upper_limit="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Triglycerides Changes Over 48 Weeks as Measured by DXA Scan</title>
        <time_frame>May 2013</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1. Lopinavir / Ritonavir + 2-3N(t)RTI</title>
            <description>Lopinavir / ritonavir + 2-3N(t)RTI: LPV/r 200mg/50mg 4 tabs once daily or 2 tabs twice daily + 2-3 N(t)RTI</description>
          </group>
          <group group_id="O2">
            <title>Arm 2. Lopinavir /Ritonavir + Raltegravir</title>
            <description>Lopinavir /ritonavir + raltegravir: LPV/r 200mg/50mg 4 tabs once daily or 2 tabs twice daily + raltegravir 400mg 1 tablet twice daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Triglycerides Changes Over 48 Weeks as Measured by DXA Scan</title>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="94"/>
                <count group_id="O2" value="105"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" lower_limit="0.3" upper_limit="0.9"/>
                    <measurement group_id="O2" value="0.8" lower_limit="0.6" upper_limit="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Total Cholesterol Changes Over 48 Weeks as Measured by DXA Scan</title>
        <time_frame>May 2013</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1. Lopinavir / Ritonavir + 2-3N(t)RTI</title>
            <description>Lopinavir / ritonavir + 2-3N(t)RTI: LPV/r 200mg/50mg 4 tabs once daily or 2 tabs twice daily + 2-3 N(t)RTI</description>
          </group>
          <group group_id="O2">
            <title>Arm 2. Lopinavir /Ritonavir + Raltegravir</title>
            <description>Lopinavir /ritonavir + raltegravir: LPV/r 200mg/50mg 4 tabs once daily or 2 tabs twice daily + raltegravir 400mg 1 tablet twice daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Total Cholesterol Changes Over 48 Weeks as Measured by DXA Scan</title>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="94"/>
                <count group_id="O2" value="105"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" lower_limit="0.1" upper_limit="0.6"/>
                    <measurement group_id="O2" value="0.6" lower_limit="0.4" upper_limit="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Glucose Changes Over 48 Weeks as Measured by DXA Scan</title>
        <time_frame>May 2013</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1. Lopinavir / Ritonavir + 2-3N(t)RTI</title>
            <description>Lopinavir / ritonavir + 2-3N(t)RTI: LPV/r 200mg/50mg 4 tabs once daily or 2 tabs twice daily + 2-3 N(t)RTI</description>
          </group>
          <group group_id="O2">
            <title>Arm 2. Lopinavir /Ritonavir + Raltegravir</title>
            <description>Lopinavir /ritonavir + raltegravir: LPV/r 200mg/50mg 4 tabs once daily or 2 tabs twice daily + raltegravir 400mg 1 tablet twice daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Glucose Changes Over 48 Weeks as Measured by DXA Scan</title>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="94"/>
                <count group_id="O2" value="105"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.04" lower_limit="-0.2" upper_limit="0.2"/>
                    <measurement group_id="O2" value="-0.1" lower_limit="-0.4" upper_limit="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Adverse Events were not planned to be analyzed for the sub-study and that complete adverse event information is included in the main study report (NCT00931463)</desc>
      <group_list>
        <group group_id="E1">
          <title>Arm 1. Lopinavir / Ritonavir + 2-3N(t)RTI</title>
          <description>Lopinavir / ritonavir + 2-3N(t)RTI: LPV/r 200mg/50mg 4 tabs once daily or 2 tabs twice daily + 2-3 N(t)RTI</description>
        </group>
        <group group_id="E2">
          <title>Arm 2. Lopinavir /Ritonavir + Raltegravir</title>
          <description>Lopinavir /ritonavir + raltegravir: LPV/r 200mg/50mg 4 tabs once daily or 2 tabs twice daily + raltegravir 400mg 1 tablet twice daily.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is a Clinical Trial Agreement signed with each PI detailing the publication policy and disclosure of study's information, in summary:
The Institution, its personnel and the Principal Investigator must not Publish or present any aspect of the Study without the prior written approval of the sponsor, except for the purposes of internal training Publications or presentations of results from the Study will follow the agreement's publication/presentation guidelines</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Prof Sean Emery</name_or_title>
      <organization>The Kirby Institute</organization>
      <phone>+61293850900</phone>
      <email>semery@kirby.unsw.edu.au</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

